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ABSTRACT: Anti-tuberculosis (TB) drug exposure is associated with a mild elevation of liver enzymes that occasionally develops 
into severe liver injury. Herein, we identify ethambutol- and rifampicin-specific CD4+ and CD8+ T-cell clones in a patient with 
fatal anti TB-related liver injury. The clones were activated to proliferate and secrete IFN-γ, Il-13 and granzyme B following drug 
treatment. Drug-responsive T-cells may contribute to the pathogenesis of anti-tuberculosis-related liver failure. 
A combination of isoniazid (INH), ethambutol (ETB), pyra-
zinamide (PZA) and/or rifampicin (RIF) is commonly used for 
the treatment of tuberculosis (TB). A mild elevation of liver 
enzymes that occasionally develops into severe liver injury 
represents a significant clinical problem.
1
 The culprit drug 
involved in the pathogenesis of anti TD-related liver injury has 
not been fully defined and the mechanism of tissue injury has 
not been resolved. The delayed onset of clinical symptoms and 
the discovery of an HLA-risk allele
2
 suggest that the adaptive 
immune system might contribute to the liver injury. Recently, 
Metushi et al. found anti-INH and anti-CYP auto antibodies in 
patients with INH-induced severe liver failure suggesting that 
INH hapten protein adducts activate humoral responses in 
patients with INH monotherapy-induced liver injury.
3
 Moreo-
ver, the authors found an increased frequency of IL-10 secret-
ing cells in patients with mild elevations in liver enzymes sug-
gesting that anti-inflammatory IL-10 could be the reason that 
more serious liver injury did not occur.
4
 Recently, we have 
characterized IL-10 secreting INH-specific CD4+ T-cell 
clones in patients with resolving forms of liver injury related 
to exposure to anti-TB drug combinations.
5
 ETB, PZA and 
RIF did not activate T-cells in these patients. The objective of 
the current study was to characterize the specificity of drug-
responsive T-cells in a case of fatal anti-TB drug-related liver 
injury.  
The patient, a 50 year old Indian male, presented 29 days after 
start of Voractiv (PZA 2000mg, RIF 600mg, ETB 1100mg, 
INH 300mg/day) treatment for pulmonary and mediastinal TB. 
He was otherwise fit and well with no previous history of drug 
allergy. His baseline liver function was in the normal range 
(alanine aminotransferase [ALT] 23IU/L). After 3 weeks med-
ication he reported feeling unwell with increased breathless-
ness, abdominal discomfort, nausea, and jaundice with eleva-
tion of ALT (262 IU/L). Blood counts (haemoglobin and total 
leukocytes and platelets) were in the normal range. Viral se-
rologies (IgM anti-HAV, IgM anti-HEV, HBsAg, anti-HCV, 
hepatitis B virus DNA, hepatitis C virus RNA) and markers 
for autoimmune liver disease (anti-nuclear antibody, anti-
smooth muscle antibody, anti-mitochondrial antibody, anti-
liver kidney microsomal antibody) were negative. Medication 
was immediately stopped and the patient was diagnosed with a 
drug-induced liver reaction. Peripheral blood mononuclear 
cells (PBMC) were collected, with approval from the local 
ethics committee and informed consent, 16h later when ALT 
levels had increased to 514IU/L (bilirubin 32mg/dL). Over the 
next few days liver function deteriorated, with ALT peaking at 
2373 IU/L, bilirubin at 459mg/dL and an INR of 4.4. He de-
veloped multi-organ failure and died 41 days after TB treat-
ment commenced. 
 
Figure 1. INH-, RIF-, ETB- and PZA-induced proliferation of T-cell 
clones. Clones were incubated with antigen presenting cells and drug 
and proliferation was measured 48h later through addition of 
[
3
H]thymidine. SI of 2 indicated by dashed line was considered posi-
tive and clones were expanded for additional studies. 
Promising biomarkers have recently been identified that pro-
vide mechanistic insight into hepatic events associated with 
idiosyncratic and acetaminophen-induced liver injury.
6 
Com-
 pared with published data in healthy donors and acetamino-
phen overdose that does not cause liver injury,
7
 all markers 
(total HMGB1 (35.6 ng/ml), mir-122 (1010.7 let-7 normal-
ized), keratin-18 M65 (8352.5 U/l), GLDH (1078.9 U/l)) were 
elevated alongside peak ALT, with the exception of keratin-10 
M30 (410.2 U/l).     
A T-cell response to the suspect drugs was initially studied  
with the acute blood sample using diagnostic assays, the lym-
phocyte transformation test and IFN- PBMC ELIspot.
8,9
 
Briefly, PBMC were cultured with INH (0.1-4mM), RIF (0.01-
0.4mM), ETB (0.01-4mM) and PZA (0.01-4mM) and prolifer-
ation and cytokine release were measured. PBMC were stimu-
lated to proliferate and secrete IFN- in the presence of the 
positive control tetanus toxoid. However, a negative result 
(i.e., stimulation index less than 2) was observed using the 4 
test compounds. These negative data during the acute reaction 
might be explained by pre-activation of the drug-specific T-
cells in the patient. In fact, Pichler and Tilch,
10
 suggest that T-
cell assays for diagnosis should be conducted 4-8 weeks after 
a reaction for this reason. 
Despite these initial negative results, drug-reactive T-cells 
were enriched by stimulation of PBMC with PZA, RIF, ETB 
and INH for two weeks. T-cell clones were generated by serial 
dilution and repetitive mitogen-driven expansion.
11
 An Ep-
stein-Barr virus-transformed B-cell line was generated and 
used as antigen-presenting cells. Reactivity of the T-cell 
clones (5x10
4
 T-cells, 1x10
4
 antigen presenting cells; 200μl 
total volume, 96 well cell culture plates) to the compounds 
was tested by measurement of proliferation using [
3
H]-
thymidine after a 48h culture period. A total of 710 clones 
were generated; 5 displayed reactivity against ethambutol and 
8 displayed reactivity against rifampicin. PZA and INH re-
sponsive clones were not detected. The ETB clones expressed 
the CD4+ co-receptor. Four RIF-responsive clones were avail-
able for phenotyping; 3 were CD4+, 1 was CD8+.  
 
Figure 2. Specificity of ETB and RIF-responsive T-cell clones. 
Clones were cultured with antigen presenting cells ± drugs (PZA was 
not included as all previous studied yielded negative results) and pro-
liferation was measured using [
3
H]thymidine (*P<0.05; Mann-
Whitney test). 
All of the ETB and RIF-responsive clones were expanded for 
dose-response studies, to assess drug specificity and to charac-
terize the secretion of cytokines and cytolytic molecules. 
Clones were stimulated to proliferate in a dose-dependent 
manner in the presence of either ETB or RIF (results not 
shown). The other drugs the patient was exposed to at the time 
of tissue injury did not activate the clones (Figure 2). These 
data show that 2 structurally divergent drugs interact with and 
activate the patients’ adaptive immune system prior to the 
development of liver failure. These data are in stark contrast to 
our earlier study utilizing PBMC from patients with reversible 
anti TB drug-related liver injury, where T-cells were selective-
ly activated with isoniazid.        
The final component of the project was to assess whether the 
clones secreted cytokines and cytolytic molecules following 
drug stimulation. Th1 and Th2 cytokines IFN- and IL-13, 
respectively, were selected for the ELIspot analysis. All ETB 
and RIF-responsive clones (including the single CD8+ clone) 
secreted IFN- and IL-13. Interestingly, the clones also secret-
ed the pro-apoptotic molecules granzyme B, which indicates 
that the clones have the ability to damage target tissue.   
 
Figure 3. Cytokine/cytolytic molecule secretion from T-cell clones. 
Clones were cultured with antigen presenting cells ± drugs and cyto-
kine secretion was visualized by ELIspot. A) Representative ELIspot 
images from 2 clones (1 ETB & 1 RIF-specific). B) Mean dose-
dependent cytokine release from the ETB and RIF clones. 
To summarize, ETB and RIF-specific CD4+ and CD8+ clones 
were generated from a patient with anti-TB drug-related liver 
failure. Our investigation of patients with resolving and this 
fatal form of liver injury show that drug-specific T-cell activa-
tion is a common feature. Although further studies with a 
larger patient cohort are required, our data suggests that isoni-
azid activates T-cells in patients with resolving forms of liver 
injury, whereas in fatal liver injury the T-cells are activated by 
other drugs such as ETB and RIF in this case. Future studies 
are on-going to characterize the risk and protective factors that 
influence individual susceptibility.  
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